Merck & Cohas reported a surge in third quarter net income, based on strong sales of key drugs, including Januvia, Janumet and Gardasil.
Diabetes medications Januvia and Janumet reported sales increases of 41% and 42% respectively over the corresponding 2010 results, amounting to sales figures of $846m and $350m.
Sales of Singulair, Merck’s leading asthma/allergic rhinitis treatment, rose 10% to $1.34bn, and it remains the company’s best-selling drug.
Company sales reached $12.02bn, representing an 8% increase, owing to a 5% boost from foreign exchange.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData